PURPOSE: We aimed to compare the diagnostic performance of PET/CT imaging performed with 68Ga-DOTA-FAPI and 18FDG in detection of liver metastases in patients with gastrointestinal system (GIS) cancer. METHODS: A total of 31 patients who underwent 68Ga-DOTA-FAPI and 18F-FDG PET/CT examinations and diagnosed with GIS cancer (15 colorectal, 9 pancreas, 4 stomach and 3 other cancers) were included in the study. The presence of liver metastasis was decided based on histopathologic diagnosis, PET/CT, other radiologic examinations or tumor biomarker findings, and both PET/CT imaging findings were compared on the patient and lesion basis. RESULTS: Of the 31 patients, 28 were found as true positive with 68Ga-DOTA-FAPI-PET/CT and 17 with 18FDG-PET/CT. Of the 98 metastatic liver lesions determined according to our diagnostic criteria, 92 were found as true positive lesions with 68Ga-DOTA-FAPI-PET/CT and 65 with 18FDG-PET/CT. There was a statistically significant difference between both imaging modalities in the patient and lesion based comparisons (p < 0.05). When semiquantitative values (SUVmax, mlr) obtained from the lesions were compared between the two imaging methods, mlr values showed statistically significant difference in all tumor subgroups (p < 0.05). CONCLUSION: It was concluded that 68Ga-DOTA-FAPI-PET/CT was superior over 18FDG-PET/CT in detection of liver metastases of GIS cancers and it can be a complementary method especially in negative cases with 18FDG-PET/CT.
PURPOSE: We aimed to compare the diagnostic performance of PET/CT imaging performed with 68Ga-DOTA-FAPI and 18FDG in detection of liver metastases in patients with gastrointestinal system (GIS) cancer. METHODS: A total of 31 patients who underwent 68Ga-DOTA-FAPI and 18F-FDG PET/CT examinations and diagnosed with GIS cancer (15 colorectal, 9 pancreas, 4 stomach and 3 other cancers) were included in the study. The presence of liver metastasis was decided based on histopathologic diagnosis, PET/CT, other radiologic examinations or tumor biomarker findings, and both PET/CT imaging findings were compared on the patient and lesion basis. RESULTS: Of the 31 patients, 28 were found as true positive with 68Ga-DOTA-FAPI-PET/CT and 17 with 18FDG-PET/CT. Of the 98 metastatic liver lesions determined according to our diagnostic criteria, 92 were found as true positive lesions with 68Ga-DOTA-FAPI-PET/CT and 65 with 18FDG-PET/CT. There was a statistically significant difference between both imaging modalities in the patient and lesion based comparisons (p < 0.05). When semiquantitative values (SUVmax, mlr) obtained from the lesions were compared between the two imaging methods, mlr values showed statistically significant difference in all tumor subgroups (p < 0.05). CONCLUSION: It was concluded that 68Ga-DOTA-FAPI-PET/CT was superior over 18FDG-PET/CT in detection of liver metastases of GIS cancers and it can be a complementary method especially in negative cases with 18FDG-PET/CT.
Authors: Shumao Zhang; Wei Wang; Tingting Xu; Haoyuan Ding; Yi Li; Huipan Liu; Yinxue Huang; Lin Liu; Tao Du; Yan Zhao; Yue Chen; Lin Qiu Journal: Front Oncol Date: 2022-07-01 Impact factor: 5.738
Authors: E Novruzov; K Dendl; H Ndlovu; P L Choyke; M Dabir; M Beu; F Novruzov; E Mehdi; F Guliyev; S A Koerber; I Lawal; G Niegisch; J Debus; U Haberkorn; M Sathekge; F L Giesel Journal: Mol Imaging Biol Date: 2022-03-29 Impact factor: 3.484
Authors: Okker D Bijlstra; Maud M E Boreel; Sietse van Mossel; Mark C Burgmans; Ellen H W Kapiteijn; Daniela E Oprea-Lager; Daphne D D Rietbergen; Floris H P van Velden; Alexander L Vahrmeijer; Rutger-Jan Swijnenburg; J Sven D Mieog; Lioe-Fee de Geus-Oei Journal: Diagnostics (Basel) Date: 2022-03-15